Search Results

You are looking at 91 - 100 of 2,716 items for :

  • Refine by Access: All x
Clear All
Full access

Carcinoma in situ of the Urinary Bladder: Review of Clinicopathologic Characteristics with an Emphasis on Aspects Related to Molecular Diagnostic Techniques and Prognosis

Nalan Nese, Ruta Gupta, Matthew H. T. Bui, and Mahul B. Amin

Edited by Kerrin G. Robinson

JI . Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases . Am J Surg Pathol 2006 ; 30 : 883 – 891 . 33 Zincke H Utz DC Farrow GM . Review of Mayo Clinic experience with carcinoma in situ

Full access

Is Biannual Surveillance for Pancreatic Cancer Sufficient in Individuals With Genetic Syndromes or Familial Pancreatic Cancer?

Yifan Wang, Adeline Cuggia, Yen-I Chen, Josée Parent, Agatha Stanek, Robert E. Denroche, Amy Zhang, Robert C. Grant, Céline Domecq, Bryn Golesworthy, Chaya Shwaartz, Ayelet Borgida, Spring Holter, Julie M. Wilson, George Chong, Grainne M. O’Kane, Jennifer J. Knox, Sandra E. Fischer, Steven Gallinger, Zu-Hua Gao, William D. Foulkes, Kevin A. Waschke, and George Zogopoulos

compared with the general population. To ascertain study eligibility, a genetic counselor (A. Cuggia) obtained a personal and, at minimum, a 3-generation family history and verified clinical diagnoses through review of medical records. Participants were

Full access

The Role of Maintenance Therapy in the Treatment of Multiple Myeloma

Ashraf Z. Badros

survival with maintenance thalidomide. (A) All trials. (B) Excluding Barlogie 2006. Abbreviations: HR, hazard ratio; OS, overall survival; SE, standard error. Adapted from Hicks LK, Haynes AE, Reece DE, et al. A meta-analysis and systematic review of

Full access

HSR20-098: A Systematic Literature Review of First-Line (1L) Treatments for Patients With MGMT (O-6-Methylguanine-DNA Methyl Transferase) Methylated and Unmethylated Glioblastoma Multiforme (GBM)

Gautamjeet Singh Mangat, Roelien Postema, Shweta Takyar, Anagha Gogate, and Alex Z. Fu

need. We reviewed published literature to assess the clinical performance of various interventions in newly diagnosed GBM by MGMT methylation status. Methods: An SLR was conducted from database inception through October 29, 2018, in accordance with

Full access

BPI20-013: A Systematic Review and Meta-Analysis on Mucocutaneous Toxicities Associated With Upfront Use of Immune Checkpoint Inhibitor and Anti-Angiogenic Tyrosine Kinase Inhibitor Combinations for Advanced Renal Cell Carcinoma

Nusrat Jahan, Francis Mogollon-Duffo, Miguel Quirch, Lukman Tijani, and Shabnam Rehman

for advanced renal cell carcinoma (aRCC). When used individually, both ICIs and VEGFis have significant mucocutaneous toxicities. We performed a systematic review and meta-analysis of phase 3 randomized controlled trials (RCTs) to determine the

Full access

Re-Engage: A Novel Nurse-Led Program for Survivors of Childhood Cancer Who Are Disengaged From Cancer-Related Care

Christina Signorelli, Claire E. Wakefield, Karen A. Johnston, Joanna E. Fardell, Jordana K McLoone, Mary-Ellen E. Brierley, Maria Schaffer, Elysia Thornton-Benko, Afaf Girgis, W. Hamish Wallace, Richard J. Cohn, and on behalf of the BSU Implementation Group*

flowchart. Abbreviations: CNC, clinical nurse consultant; GP, general practitioner; MDT, multidisciplinary review. a High-risk = specialist/MDT care; low/medium-risk = primary services with specialist input where needed. Outcomes and Measures We collected

Full access

Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time

Amanda Putri Rahmadian, Seanthel Delos Santos, Shruti Parshad, Louis Everest, Matthew C. Cheung, and Kelvin K. Chan

ratios were conducted using Review Manager software (version 5.3) to estimate overall absolute and relative survival benefits of the drugs and to compare those of immunotherapy versus nonimmunotherapy. We classified drugs as either immunotherapy or

Full access

Should the ASCO/ASH Guidelines for the Use of Intravenous Iron in Cancer- and Chemotherapy-Induced Anemia Be Updated?

Anat Gafter-Gvili, David P. Steensma, and Michael Auerbach

, similar to that seen in patients with hereditary hemochromatosis, by causing free radical-induced DNA damage by Fenton chemistry. Although none of the IV iron studies reviewed earlier had long-term cancer outcomes as a primary end point, post hoc analyses

Full access

BPI19-013: Use of Clinical Decision Support and Peer Review to Increase NCCN Guidelines Adherence

Eric Gratias, David Spangler, and Margaret Rausa

Background: eviCore healthcare uses the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) to support its proprietary program for medical oncology drug management. All treatment regimens assigned NCCN Category of Evidence 1, 2A, or 2B are considered NCCN-adherent treatment selections in the eviCore program. The purpose of this study was to evaluate the pattern of NCCN adherence during the first year following program launch in regional payer markets. Methods: All cancer drug treatment authorization requests submitted in month 1 and month 12 following program launch for 4 regional third-party payers representing 13 different states were included, each of whom had management of high cost oncology drugs in place prior to eviCore program launch. Month 1 data were used as a surrogate for pre-program NCCN adherence, which is an overestimate as there is significant eviCore program impact on patients initiating therapy during that time. Requests with incomplete clinical data were excluded from analysis. Included requests were stratified by month 1 or month 12 from initial program launch date for each health plan. NCCN adherence was assigned based on the results of the clinical decision support and peer consultation processes utilized by eviCore to adjudicate the treatment request. NCCN adherence rate was calculated for each subgroup and a cumulative NCCN adherence rate for all included cases was calculated using weighted average accounting for volume differences by market. Results: There were 2,028 treatment regimen requests that were fully evaluable, with 1,285 occurring in month 1 and 743 occurring in month 12 following program launch. The rate of NCCN adherence increased for each health plan during the first program year, ranging from 69%–84% in month 1 and rising to 79%–91% in month 12. The weighted cumulative NCCN adherence during month 1 for all included plans was 75% and rose to 88% at month 12 following program launch. Conclusions: Use of clinical decision support supplemented by peer consultation is an effective means of increasing oncologists’ adherence to NCCN-recommended therapies across a broad range of regional provider markets. Additional study is warranted to determine whether this methodology can be applied to NCCN Categories of Preference to direct more patients toward preferred regimens with superior efficacy, safety, and affordability to further improve quality of care and lower total medical costs.

Full access

QIM24-183: Novel Therapies in the Oncology Care Model: A Profile in Review.

Puneeth Indurlal and Lalan S. Wilfong